Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Ischemia diagnostic study: Cambridge Heart has initiated a 200-patient study to evaluate microvolt T-wave alternans testing in detection of ischemia in patients with known or suspected coronary artery disease, the firm announced July 6. The company is hoping to show that MTWA, which allows real-time intra-cardiac measurements of heart rhythm irregularities, can enhance the diagnosis of underlying ischemia; currently, the test, conducted on its HearTwave II system, is used to assess the risk of potentially fatal arrhythmias. Enrollment in the trial is expected to wrap up in mid-2011. "If the results of the pilot study confirm our finding, we will begin a larger study [in] the second half of 2011," according to Cambridge Heart CEO Ali Haghighi-Mood. The firm announced it had licensed the patent for the incorporation of MWTA in implantable medical devices from MIT in 2008 (1"The Gray Sheet" June 30, 2008)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT029122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel